TY - JOUR
T1 - The Collaborative Ocular Tuberculosis Study (COTS)-1
T2 - A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis
AU - Agrawal, Rupesh
AU - Gunasekeran, Dinesh Visva
AU - Agarwal, Aniruddha
AU - Carreño, Ester
AU - Aggarwal, Kanika
AU - Gupta, Bhaskar
AU - Raje, Dhananjay
AU - Murthy, Somasheila I.
AU - Westcott, Mark
AU - Chee, Soon Phaik
AU - McCluskey, Peter
AU - Ling, Ho Su
AU - Teoh, Stephen
AU - Cimino, Luca
AU - Biswas, Jyotirmay
AU - Narain, Shishir
AU - Agarwal, Manisha
AU - Mahendradas, Padmamalini
AU - Khairallah, Moncef
AU - Jones, Nicholas
AU - Tugal-Tutkun, Ilknur
AU - Babu, Kalpana
AU - Basu, Soumayava
AU - Lee, Richard
AU - Al-Dhibi, Hassan
AU - Bodaghi, Bahram
AU - Invernizzi, Alessandro
AU - Goldstein, Debra A.
AU - Herbort, Carl P.
AU - Barisani-Asenbauer, Talin
AU - González-López, Julio J.
AU - Androudi, Sofia
AU - Bansal, Reema
AU - Moharana, Bruttendu
AU - Mahajan, Sarakshi
AU - Esposti, Simona
AU - Tasiopoulou, Anastasia
AU - Nadarajah, Sengal
AU - Agarwal, Mamta
AU - Abraham, Sharanya
AU - Vala, Ruchi
AU - Lord, Joanne
AU - Singh, Ramandeep
AU - Sharma, Aman
AU - Sharma, Kusum
AU - Zierhut, Manfred
AU - Kon, Onn Min
AU - Kempen, John
AU - Cunningham, Emmett T.
AU - Rousselot, Andres
AU - Nguyen, Quan Dong
AU - Pavesio, Carlos
AU - Gupta, Vishali
N1 - Funding Information:
The research was partially funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. This sponsor supported some of the research man-hours that were contributed by all our part-time collaborators from the Moorfields Eye Hospital that are salaried as Ophthalmology clinicians by the hospital. Debra A. Goldstein is supported by an unrestricted grant from Research to Prevent Blindness (RPB). Vishali Gupta is supported by grant from Department of Biotechnology (DBT), India. Julio J Gonalez-Lopez is supported by study grants from AbbVie, Allergan, and Angelini.
Publisher Copyright:
©, Taylor & Francis Group, LLC.
PY - 2020
Y1 - 2020
N2 - Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU). Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed. Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06). Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.
AB - Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU). Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed. Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06). Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.
KW - Anti-tubercular therapy
KW - choroiditis
KW - ocular
KW - tuberculosis
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=85053279767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053279767&partnerID=8YFLogxK
U2 - 10.1080/09273948.2018.1489061
DO - 10.1080/09273948.2018.1489061
M3 - Article
C2 - 30156979
AN - SCOPUS:85053279767
SN - 0927-3948
VL - 28
SP - 38
EP - 48
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - sup1
ER -